{"altmetric_id": 89098561, "counts": {"readers": {"citeulike": "0", "mendeley": "33", "connotea": "0"}, "total": {"posts_count": 72}, "twitter": {"unique_users_count": 53, "posts_count": 57}, "news": {"unique_users_count": 15, "unique_users": ["pr_newswire", "ticker_tech", "finanzen_ch", "morning_star", "wfmz_tv_69", "benzinga", "profitquotes_com", "the_street", "kpvi", "the_record", "pharmiweb", "jotup", "biospace", "drug_target_review", "trialsite_news"], "posts_count": 15}}, "citation": {"altmetric_jid": "532721422a83ee84788b4567", "authors": ["de Vries, Maren", "Mohamed, Adil S", "Prescott, Rachel A", "Valero-Jimenez, Ana M", "Desvignes, Ludovic", "O\u2019Connor, Rebecca", "Steppan, Claire", "Devlin, Joseph C", "Ivanova, Ellie", "Herrera, Alberto", "Schinlever, Austin", "Loose, Paige", "Ruggles, Kelly", "Koralov, Sergei B", "Anderson, Annaliesa S.", "Binder, Joseph", "Dittmann, Meike"], "doi": "10.1101/2020.08.28.272880", "first_seen_on": "2020-08-29T00:16:36+00:00", "funders": ["niaid", "nci", "nhlbi"], "issns": [], "journal": "bioRxiv", "last_mentioned_on": 1614078681, "links": ["https://www.biorxiv.org/content/10.1101/2020.08.28.272880v1", "http://biorxiv.org/cgi/content/short/2020.08.28.272880", "https://www.biorxiv.org/content/10.1101/2020.08.28.272880v1.full", "https://pubmed.ncbi.nlm.nih.gov/32869028/", "https://c212.net/c/link/?t=0&l=en&o=2918118-1&h=1999164863&u=https://www.biorxiv.org/content/10.1101/2020.08.28.272880v1&a=bioRxiv", "https://www.biorxiv.org/content/10.1101/2020.08.28.272880v2"], "pdf_url": "https://www.biorxiv.org/content/biorxiv/early/2020/08/28/2020.08.28.272880.full.pdf", "pmid": "32869028", "publisher": "Cold Spring Harbor Laboratory", "title": "A comparative analysis of SARS-CoV-2 antivirals in human airway models characterizes 3CLpro inhibitor PF-00835231 as a potential new treatment for COVID-19", "type": "article", "mendeley_url": "https://www.mendeley.com/catalogue/06cfb06e-1c0f-3eb4-b952-403db88ee828/"}, "altmetric_score": {"score": 134.7, "score_history": {"1y": 134.7, "6m": 3.5, "3m": 0.5, "1m": 0, "1w": 0, "6d": 0, "5d": 0, "4d": 0, "3d": 0, "2d": 0, "1d": 0, "at": 134.7}, "context_for_score": {"all": {"total_number_of_other_articles": 17463360, "mean": 9.398098837908, "rank": 173279, "this_scored_higher_than_pct": 99, "this_scored_higher_than": 17290261, "rank_type": "exact", "sample_size": 17463360, "percentile": 99}, "similar_age_3m": {"total_number_of_other_articles": 306196, "mean": 17.914478712981, "rank": 6470, "this_scored_higher_than_pct": 97, "this_scored_higher_than": 299724, "rank_type": "exact", "sample_size": 306196, "percentile": 97}, "this_journal": {"total_number_of_other_articles": 118256, "mean": 13.84256225477, "rank": 1030, "this_scored_higher_than_pct": 99, "this_scored_higher_than": 117229, "rank_type": "exact", "sample_size": 118256, "percentile": 99}, "similar_age_this_journal_3m": {"total_number_of_other_articles": 9211, "mean": 13.115239821952, "rank": 84, "this_scored_higher_than_pct": 99, "this_scored_higher_than": 9128, "rank_type": "exact", "sample_size": 9211, "percentile": 99}}}, "demographics": {"poster_types": {"member_of_the_public": 32, "researcher": 19, "practitioner": 2}, "users": {"twitter": {"cohorts": {"Members of the public": 32, "Scientists": 19, "Practitioners (doctors, other healthcare professionals)": 2}}, "mendeley": {"by_status": {"Student  > Postgraduate": 1, "Researcher": 8, "Student  > Master": 5, "Student  > Ph. D. Student": 2, "Professor": 1, "Student  > Bachelor": 2, "Other": 3, "Librarian": 3, "Lecturer > Senior Lecturer": 1, "Unspecified": 2}, "by_discipline": {"Engineering": 2, "Chemistry": 3, "Medicine and Dentistry": 9, "Social Sciences": 1, "Economics, Econometrics and Finance": 1, "Immunology and Microbiology": 3, "Agricultural and Biological Sciences": 1, "Nursing and Health Professions": 2, "Biochemistry, Genetics and Molecular Biology": 3, "Environmental Science": 1, "Unspecified": 2}}}, "geo": {"twitter": {"US": 28, "BE": 1, "DE": 3, "GB": 1, "FR": 1, "PR": 1, "JP": 1}}}, "posts": {"twitter": [{"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "1949132852"}, "tweet_id": "1299501112928743426"}, {"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "748908558066982916"}, "tweet_id": "1299501113989881858"}, {"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "850712117573537793"}, "tweet_id": "1299586954196135936"}, {"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "1256280966101942273"}, "tweet_id": "1299695268326256643"}, {"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "4901919879"}, "tweet_id": "1300060062782717953"}, {"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "4901919879"}, "tweet_id": "1300060084794425344"}, {"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "4901919879"}, "tweet_id": "1300061231341096962"}, {"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "1265336030833422337"}, "tweet_id": "1300869677627834368"}, {"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "1244711417657376768"}, "tweet_id": "1300882653802004482"}, {"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "392413519"}, "tweet_id": "1305360408367304706"}, {"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "963151536938401792"}, "tweet_id": "1306007747083763718"}, {"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "1085135632496766978"}, "tweet_id": "1306009674731393025"}, {"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "767237941"}, "tweet_id": "1306014908778151936"}, {"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "824409090613006336"}, "tweet_id": "1306020341618290688"}, {"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "1114239488681750530"}, "tweet_id": "1306023194751578113"}, {"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "2464051087"}, "tweet_id": "1306025898056077313"}, {"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "892120710667264001"}, "tweet_id": "1306025958114197504"}, {"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "27637748"}, "tweet_id": "1306026204529659906"}, {"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "753927090471333888"}, "tweet_id": "1306029537285808129"}, {"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "1223307253236817922"}, "tweet_id": "1306032579011923971"}, {"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "1148666577287618561"}, "tweet_id": "1306035095292260352"}, {"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "1142919882306179073"}, "tweet_id": "1306035450839273473"}, {"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "300351538"}, "tweet_id": "1306035735821201408"}, {"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "1240995101234434050"}, "tweet_id": "1306041664507506689"}, {"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "914179815334449153"}, "tweet_id": "1306052400361463808"}, {"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "3180636202"}, "tweet_id": "1306054358254202882"}, {"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "1065278227206324224"}, "tweet_id": "1306056634137968640"}, {"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "1280878711454273543"}, "tweet_id": "1306059008730705920"}, {"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "37877332"}, "tweet_id": "1306072989008625664"}, {"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "139358002"}, "tweet_id": "1306105542851653632"}, {"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "1248981326188826637"}, "tweet_id": "1306110245874225152"}, {"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "1156537447364333568"}, "tweet_id": "1306118274611064837"}, {"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "1246384583496601600"}, "tweet_id": "1306118489200041987"}, {"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "916093467918524416"}, "tweet_id": "1306195446759657473"}, {"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "1118717099646566400"}, "tweet_id": "1306204391700140034"}, {"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "927174250846400513"}, "tweet_id": "1306205836612599818"}, {"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "984172899308392448"}, "tweet_id": "1306226787035344903"}, {"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "33851419"}, "tweet_id": "1306238606172983301"}, {"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "51740981"}, "tweet_id": "1306242012933492739"}, {"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "999100031239118853"}, "tweet_id": "1306246480907378690"}, {"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "810995201112231940"}, "tweet_id": "1306247253477261315"}, {"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "1305903716755804160"}, "tweet_id": "1306255270184660992"}, {"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "14574087"}, "tweet_id": "1306260438145998848"}, {"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "1056508862"}, "tweet_id": "1306263307444277253"}, {"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "976242188299522049"}, "tweet_id": "1306344403120910337"}, {"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "235776953"}, "tweet_id": "1306405636985495554"}, {"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "1219774000861188097"}, "tweet_id": "1306442741958795264"}, {"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "3956049136"}, "tweet_id": "1306504074662211585"}, {"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "1110320702471716865"}, "tweet_id": "1306636807732449281"}, {"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "1028413513885208578"}, "tweet_id": "1306751857927299072"}, {"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "1280878711454273543"}, "tweet_id": "1306779094349156354"}, {"license": "gnip", "citation_ids": [89098561, 90029906], "author": {"tweeter_id": "1237188964546760705"}, "tweet_id": "1322992188435955714"}, {"license": "gnip", "citation_ids": [89098561, 90029906], "author": {"tweeter_id": "1237188964546760705"}, "tweet_id": "1323019360026480642"}, {"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "2991716510"}, "tweet_id": "1325927589639282688"}, {"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "373937315"}, "tweet_id": "1337024640020049921"}, {"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "141393630"}, "tweet_id": "1363478643415080967"}, {"license": "gnip", "citation_ids": [89098561], "author": {"tweeter_id": "4183374254"}, "tweet_id": "1364170982252900359"}], "news": [{"title": "Experimental COVID-19 Drug Shows Promise in Preliminary Cell Research", "url": "http://ct.moreover.com/?a=43082531623&p=1pl&v=1&x=TXwgZyDeVz8wVcQ59lTjYQ", "license": "public", "citation_ids": [89098561], "posted_on": "2020-09-15T17:45:00+00:00", "summary": "NEW YORK, Sept. 15, 2020 /PRNewswire/ -- An early study in human cells found that an antiviral drug candidate, Pfizer Inc.'s PF-00835231, may be at least as potent as the drug remdesivir in blocking the reproduction of the virus that causes COVID-19.", "author": {"name": "PR Newswire", "url": "http://www.prnewswire.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/545/normal/Screen_Shot_2016-01-06_at_16.29.18.png?1452097789"}}, {"title": "Experimental COVID-19 Drug Shows Promise in Preliminary Cell Research", "url": "http://ct.moreover.com/?a=43082536408&p=1pl&v=1&x=41lyS8tDl8tw0smkAa4DFQ", "license": "public", "citation_ids": [89098561], "posted_on": "2020-09-15T17:48:52+00:00", "summary": "NEW YORK, Sept. 15, 2020 /PRNewswire/ -- An early study in human cells found that an antiviral drug candidate, Pfizer Inc.'s PF-00835231, may be at least as potent as the drug remdesivir in blocking the reproduction of the virus that causes COVID-19.", "author": {"name": "Ticker Tech", "url": "http://www.tickertech.com", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/724/normal/Screen_Shot_2016-01-26_at_15.37.40.png?1453822700"}}, {"title": "Experimental COVID-19 Drug Shows Promise in Preliminary Cell Research", "url": "http://ct.moreover.com/?a=43082540398&p=1pl&v=1&x=ON8voN6bR-rt861jFxkk_Q", "license": "public", "citation_ids": [89098561], "posted_on": "2020-09-15T17:45:00+00:00", "summary": "NEW YORK, Sept. 15, 2020 /PRNewswire/ -- An early study in human cells found that an antiviral drug candidate, Pfizer Inc.'s PF-00835231, may be at least as potent as the drug remdesivir in blocking the reproduction of the virus that causes COVID-19.", "author": {"name": "Finanzen.ch", "url": "https://www.finanzen.ch/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/573/normal/Capture26.PNG?1575886265"}}, {"title": "Experimental COVID-19 Drug Shows Promise in Preliminary Cell Research", "url": "http://ct.moreover.com/?a=43082569411&p=1pl&v=1&x=cthDxoMa3r3Xg9mze19nRQ", "license": "public", "citation_ids": [89098561], "posted_on": "2020-09-15T17:45:00+00:00", "summary": "Experimental COVID-19 Drug Shows Promise in Preliminary Cell Research PR Newswire NEW YORK, Sept.", "author": {"name": "Morning Star", "url": "https://www.morningstar.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/002/912/normal/Screen_Shot_2018-09-17_at_18.20.59.png?1537204915"}}, {"title": "Experimental COVID-19 Drug Shows Promise in Preliminary Cell Research", "url": "http://ct.moreover.com/?a=43082586356&p=1pl&v=1&x=5uRP624S4UVi8NvZMs_Ikw", "license": "public", "citation_ids": [89098561], "posted_on": "2020-09-15T17:45:00+00:00", "summary": "NEW YORK, Sept. 15, 2020 /PRNewswire/ -- An early study in human cells found that an antiviral drug candidate, Pfizer Inc.'s PF-00835231, may be at least as potent as the drug remdesivir in blocking the reproduction of the virus that causes COVID-19.", "author": {"name": "WFMZ-TV 69", "url": "https://www.wfmz.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/003/256/normal/Capture_62.PNG?1567141986"}}, {"title": "Experimental COVID-19 Drug Shows Promise in Preliminary Cell Research", "url": "http://ct.moreover.com/?a=43082603683&p=1pl&v=1&x=B2Oq7reo3c6iBE8uxg3qMA", "license": "public", "citation_ids": [89098561], "posted_on": "2020-09-15T17:45:00+00:00", "summary": "NEW YORK, Sept. 15, 2020 /PRNewswire/ -- An early study in human cells found that an antiviral drug candidate, Pfizer Inc.'s PF-00835231, may be at least as potent as the drug remdesivir in blocking the reproduction of the virus that causes COVID-19.", "author": {"name": "Benzinga", "url": "http://www.benzinga.com", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/738/normal/Screen_Shot_2016-01-26_at_15.59.27.png?1453824001"}}, {"title": "Experimental COVID-19 Drug Shows Promise in Preliminary Cell Research", "url": "http://ct.moreover.com/?a=43082647862&p=1pl&v=1&x=nmA_3vEftUud9wn493MJaw", "license": "public", "citation_ids": [89098561], "posted_on": "2020-09-15T18:04:12+00:00", "summary": "NEW YORK, Sept. 15, 2020 /PRNewswire/ -- An early study in human cells found that an antiviral drug candidate, Pfizer Inc.'s PF-00835231, may be at least as potent as the drug remdesivir in blocking the reproduction of the virus that causes COVID-19.", "author": {"name": "ProfitQuotes.com", "url": "http://www.profitquotes.com/cgi/?a=news&ticker=a&w=&story=201908201908021405PR_NEWS_USPR_____DC29726", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/003/276/normal/logo7E.jpg?1567155044"}}, {"title": "Experimental COVID-19 Drug Shows Promise In Preliminary Cell Research", "url": "http://ct.moreover.com/?a=43082679818&p=1pl&v=1&x=G4crcFeNvPaplv3FeNhn7A", "license": "public", "citation_ids": [89098561], "posted_on": "2020-09-15T17:45:00+00:00", "summary": "NEW YORK, Sept. 15, 2020 /PRNewswire/ -- An early study in human cells found that an antiviral drug candidate, Pfizer Inc.", "author": {"name": "The Street", "url": "http://www.thestreet.com", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/809/normal/Screen_Shot_2016-01-27_at_10.05.56.png?1453889412"}}, {"title": "Experimental COVID-19 Drug Shows Promise in Preliminary Cell Research", "url": "http://ct.moreover.com/?a=43082680452&p=1pl&v=1&x=PNnYlYHH-X5LQhappqezlA", "license": "public", "citation_ids": [89098561], "posted_on": "2020-09-15T17:45:00+00:00", "summary": "NEW YORK, Sept. 15, 2020 /PRNewswire/ -- An early study in human cells found that an antiviral drug candidate, Pfizer Inc.'s PF-00835231, may be at least as potent as the drug remdesivir in blocking the reproduction of the virus that causes COVID-19.", "author": {"name": "KPVI", "url": "https://www.kpvi.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/663/normal/Capture_kvpi.PNG?1576132656"}}, {"title": "Experimental COVID-19 Drug Shows Promise in Preliminary Cell Research", "url": "http://ct.moreover.com/?a=43082702194&p=1pl&v=1&x=6eIc8i_LK1WSStao6uOzaA", "license": "public", "citation_ids": [89098561], "posted_on": "2020-09-15T17:45:00+00:00", "summary": "NEW YORK, Sept. 15, 2020 /PRNewswire/ -- An early study in human cells found that an antiviral drug candidate, Pfizer Inc.'s PF-00835231, may be at least as potent as the drug remdesivir in blocking the reproduction of the virus that causes COVID-19.", "author": {"name": "The Record", "url": "https://www.troyrecord.com", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/003/263/normal/troyre.png?1567147129"}}, {"title": "Experimental COVID-19 Drug Shows Promise in Preliminary Cell Research", "url": "http://ct.moreover.com/?a=43082775346&p=1pl&v=1&x=kkaxWYhGeqQdFJGN39o06A", "license": "public", "citation_ids": [89098561], "posted_on": "2020-09-15T18:26:17+00:00", "summary": "NEW YORK, Sept. 15, 2020 /PRNewswire/ -- An early study in human cells found that an antiviral drug candidate, Pfizer Inc.'s PF-00835231, may be at least as potent as the drug remdesivir in blocking the reproduction of the virus that causes COVID-19.", "author": {"name": "PharmiWeb", "url": "https://www.pharmiweb.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/002/921/normal/Screen_Shot_2018-09-17_at_18.39.39.png?1537206114"}}, {"title": "Experimental COVID-19 Drug Shows Promise in Preliminary Cell Research", "url": "http://ct.moreover.com/?a=43082851554&p=1pl&v=1&x=6I11Wrc2SkErmIIviKYHIg", "license": "public", "citation_ids": [89098561], "posted_on": "2020-09-15T18:39:57+00:00", "summary": "PF-00835231 was shown in preliminary research conducted by NYU Grossman School of Medicine and Pfizer to block the action of the viral enzyme 3CLpro (Mpro).", "author": {"name": "Jotup", "url": "https://jotup.co/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/003/231/normal/jotup-logo.png?1567071493"}}, {"title": "Experimental COVID-19 Drug Shows Promise in Preliminary Cell Research", "url": "http://ct.moreover.com/?a=43086092861&p=1pl&v=1&x=0VDGN_fLRu4xXAsdlsQx5A", "license": "public", "citation_ids": [89098561], "posted_on": "2020-09-16T05:13:15+00:00", "summary": "NEW YORK, Sept. 15, 2020 /PRNewswire/ -- An early study in human cells found that an antiviral drug candidate, Pfizer Inc.", "author": {"name": "Biospace", "url": "http://www.biospace.com", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/375/normal/biospace.png?1437140433"}}, {"title": "Novel antiviral drug candidate blocks SARS-CoV-2 reproduction in cells", "url": "http://ct.moreover.com/?a=43088222377&p=1pl&v=1&x=mxkMMkzUnn5LAT1oSKf7fQ", "license": "public", "citation_ids": [89098561], "posted_on": "2020-09-16T10:55:55+00:00", "summary": "In human cells, a drug candidate called PF-00835231 has demonstrated success at blocking the reproduction of SARS-CoV-2.", "author": {"name": "Drug Target Review", "url": "https://www.drugtargetreview.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/897/normal/Capture1.PNG?1576744650"}}, {"title": "Pfizer Takes Antiviral Drug PF-07304814 into Phase 1 Clinical Trial Targeting COVID-19", "url": "https://www.trialsitenews.com/pfizer-takes-antiviral-drug-pf-07304814-into-phase-1-clinical-trial-targeting-covid-19/", "license": "public", "citation_ids": [89098561, 90029906, 89281512], "posted_on": "2020-09-21T21:30:07+00:00", "summary": "Pfizer has initiated a Phase 1 clinical trial for a novel small molecule called PF-07304814, a compound targeting an enzyme that SARS-COV-2 uses to organize and multiply\u2014the 3CL protease.", "author": {"name": "TrialSite News", "url": "https://www.trialsitenews.com", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/003/110/normal/Screenshot_2019-07-12_at_12.25.34.png?1562930787"}}]}, "score": 134.7, "images": {"small": "https://badges.altmetric.com/?size=64&score=135&types=mmtttttt", "medium": "https://badges.altmetric.com/?size=100&score=135&types=mmtttttt", "large": "https://badges.altmetric.com/?size=180&score=135&types=mmtttttt"}}